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Abstract 
The MAFB protein is a basic leucine zipper (bZIP) 
transcription factor that plays important roles both in 
development and in the regulation of lineage-
specific hematopoiesis. This gene contains no 
introns. The abnormal function of MAFB has been 
implicated in multiple myeloma, myeloid leukemias, 
multicentric carpotarsal osteolysis, Dupuytren's 
disease and nonsyndromic cleft lip. 
Keywords 
MAFB, KRML, MCTO, multiple myeloma, myeloid 
leukemia, multicentric carpotarsal osteolysis 
Identity 
Other names: KRML, MCTO 
HGNC (Hugo): MAFB 
Location: 20q12 
DNA/RNA 
Note 
The MAFB open reading frame is encoded by a 
unique exon. 
Description 
MAFB gene maps to chromosome 20q11.2-q13.1, 
consists of a single exon and spans around 3 kb 
(Cordes and Barsh, 1994; Sieweke et al., 1996). 
Transcription 
1 exon, 3378 bp.  
Ubiquitous expression of MAFB. 
Protein 
Note 
MAF family members, such as MAFB, are basic 
region/leucine zipper transcription factors that affect 
transcription positively or negatively, depending on 
their partner proteins and the context of the target 
promoter (Wang et al., 1999). 
Description 
Sequence length: 323 aa. 
Molecular mass of 35792 Da. 
Sequence similarities: MAFB belongs to the bZIP 
family. MAF family contains one bZIP (basic-
leucine zipper) domain. 
Expression 
MAFB is expressed in the digestive, endocrine and 
in immature myeloid/monocytic cells but not in 
lymphocytes. 
Localisation 
Intracellular, nucleus. 
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Protein structure of MAFB. 
 
 
Function 
Transcription factor; DNA binding protein. 
MAFB acts as a transcriptional activator or 
repressor. It plays a role in erythroid differentiation 
and in the haematopoietic system it is expressed in 
immature myeloid/monocytic cells but not in 
lymphocytes (Kelly et al., 2000). MAFB plays a 
pivotal role in regulating lineage-specific 
hematopoiesis by repressing ETS1-mediated 
transcription of erythroid-specific genes in myeloid 
cells (Zanocco-Marani et al., 2009). It is also 
required for monocytic, macrophage, podocyte and 
islet beta cell differentiation (Kelly et al., 2000; 
Sevinsky et al., 2004; Bakri et al., 2005; Gemelli et 
al., 2008; Vanhoose et al., 2008; Aziz et al., 2009). 
SUMO modification controls its transcriptional 
activity and ability to specify macrophage fate 
(Tillmanns et al., 2007). Together with MAFA, 
MAFB regulates PDX1 transcription in pancreatic 
beta cells (Vanhoose et al., 2008). It is also involved 
in renal tubule survival and F4/80 maturation 
(Moriguchi et al., 2006). This protein activates the 
insulin and glucagon promoters. Together with 
PAX6, MAFB transactivates weakly the glucagon 
gene promoter through the G1 element (Gosmain et 
al., 2010). MAFB induces osteoclastogenesis and is 
essential for normal renal development (Zankl et al., 
2012). It is a regulator of hindbrain segmentation and 
interacts with the ICD of LRP1 through a leucine 
zipper domain (Petersen et al., 2004). It is involved 
either as an oncogene or as a tumor suppressor, 
depending on the cell context, in multiple myeloma 
and myeloid leukemia development (Eychène et al., 
2008). 
It is implicated in the following physiological 
biological processes: rhombomere 6 development; 
segment specification; negative regulation of 
erythrocyte differentiation; inner ear morphogenesis; 
sensory organ development; transcription, DNA-
dependent; thymus development; T cell 
differentiation in the thymus; positive regulation of 
transcription from RNA polymerase II promoter; 
respiratory gaseous exchange; rhombomere 5 
development; brain segmentation. 
Homology 
MAFB shares 84% amino acid identity with its 
murine homolog. 
Implicated in 
Multiple myeloma 
Disease 
Multiple myeloma, also known as plasma cell 
myeloma, is a cancer of plasma cells. In multiple 
myeloma, collections of abnormal plasma cells 
accumulate in the bone marrow, where they interfere 
with the production of normal blood cells. Most 
cases of multiple myeloma also feature the 
production of a paraprotein - an abnormal antibody 
which can cause kidney problems. Bone lesions and 
hypercalcemia (high blood calcium levels) are also 
often encountered. MAFB is a specific marker for 
the prognostic unfavorable t(14;20)(q32;q12) in 
multiple myeloma patients (Stralen et al., 2009). 
Prognosis 
With high-dose therapy followed by autologous stem 
cell transplantation, the median survival has been 
estimated to be approximately 4.5 years in 2013, 
compared to a median of approximately 3.5 years 
with "standard" therapy (Child et al., 2003). Overall 
the 5-year survival rate is around 35% (Seiter et al., 
2013). 
Cytogenetics 
Translocation t(14;20)(q32;q12). 
Hybrid/Mutated gene 
IGH-MAFB given rise to and aberrant expression of 
MAFB. 
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Translocation t(14;20) is implicated in multiple myeloma. Chromosomal translocations of the immunoglobulin heavy chain (IgH) 
gene region at 14q32 are regularly involved in B lymphoid malignancies. The recurrent translocation t(14;20)(q32;q12) in multiple 
myeloma results in aberrant expression of MAFB. 
 
Abnormal protein 
No fusion protein. Only aberrant expression of 
MAFB. 
Oncogenesis 
Human plasma cell neoplasias are thought to 
develop from either differentiated B cells or plasma 
cells. However, when the expression of MAF 
oncogenes (associated to human plasma cell 
neoplasias) are targeted to mouse B cells, the 
resulting animals fail to reproduce the human 
disease. An engineered transgenic mice that express 
MafB in haematopoietic stem/progenitor cells 
(HS/PCs) reproduced human multiple myeloma 
disease suggesting that, mechanistically, the 
haematopoietic progenitor population can be the 
target for transformation in MafB-associated plasma 
cell neoplasias (Vicente-Dueñas et al., 2012b). And 
the loss of p53 exacerbates this tumor stem cell 
reprogramming process (Vicente-Dueñas et al., 
2012a). 
Myeloid leukemia 
Note 
MAFB gene is deleted in myeloid leukemias (Wang 
et al., 1999). A deletion of the long arm of 
chromosome 20 [del(20q)] is a recurring 
abnormality in a wide spectrum of myeloid 
disorders. Loss of genetic material from 20q seems 
to confer a proliferative advantage to myeloid cells, 
possibly through loss of function of a tumor 
suppressor gene (Wang et al., 1998). 
Disease 
Myeloid leukemia is a type of leukemia affecting 
myeloid tissue. There are two main types, acute 
myeloid leukemia and chronic myelogenous 
leukemia. 
Cytogenetics 
Deletion of the long arm of chromosome 20. 
Multicentric carpotarsal osteolysis 
(MCTO) 
Note 
Multicentric carpotarsal osteolysis is due to a 
heterozygosity missense mutations in the MAFB 
gene. The mutations were clustered within a 51-bp 
region of the single exon of MAFB at the N-terminal 
transcription activation domain. The allelic variants 
are: THR62PRO; SER70ALA; SER70LEU; 
PRO71SER; PRO71LEU and PRO54LEU (Zankl et 
al., 2012). 
Disease 
Defects in MAFB are the cause of multicentric 
carpotarsal osteolysis syndrome (MCTO). MCTO is 
a rare skeletal disorder, usually presenting in early 
childhood with a clinical picture mimicking juvenile 
rheumatoid arthritis. Progressive destruction of the 
carpal and tarsal bone usually occurs and other bones 
may also be involved.  
Chronic renal failure is a frequent component of the 
syndrome.  
Mental retardation and minor facial anomalies have 
been noted in some patients. The main clinical 
features are progressive destruction of the carpal and 
tarsal bone and other bones may also be involved, 
associated with chronic renal failure, mental 
retardation and minor facial anomalies. 
Dupuytren's disease (DD) 
Note 
Microarray analysis identified significantly 
upregulatation of MAFB among other genes in 
Dupuytren's disease. MAFB immunohistochemistry 
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showed positive staining in 50% of the DD 
specimens studied (Lee et al., 2006). 
Disease 
Dupuytren's disease is characterized by fibroblastic 
proliferation of the palmar fascia, often leading to 
flexion contracture in the hand, where the fingers 
bend towards the palm and cannot be fully extended 
(Lee et al., 2006).  
Dupuytren's contracture progresses slowly and is 
often accompanied by some aching and itching. In 
patients with this condition, the palmar fascia 
thickens and shortens so that the tendons connected 
to the fingers cannot move freely. Incidence 
increases after the age of 40. 
Nonsyndromic cleft lip (NSCLP) 
Note 
Nonsyndromic cleft lip with or without cleft palate 
is a common isolated orofacial birth defect. The 
etiology of NSCLP is complex with both genetic and 
environmental factors implicated, but to date 
approximately only 20% of the genetic susceptibility 
has been identified (Vieira, 2008). Genome-wide 
association studies support for the association of 
MAFB and NSCLP (Yuan et al., 2011). 
Disease 
Cleft lip is a type of clefting congenital deformity 
caused by abnormal facial development during 
gestation. It is the non-fusion of the body's natural 
structures that form before birth. A cleft lip or palate 
can be successfully treated with surgery, especially 
so if conducted soon after birth or in early childhood. 
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